Biosciences
The Anopheles coluzzii range extends into Kenya: detection, insecticide resistance profiles and population genetic structure in relation to conspecific populations in West and Central Africa.Kamau L, Bennett KL, Ochomo E, Herren J, Agumba S, Otieno S, Omoke D, Matoke-Muhia D, Mburu D, Mwangangi J, Ramaita E, Juma EO, Mbogo C, Barasa S, Miles A
Malar J, (2024). 23:122
Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity against Plasmodium falciparum parasites.Ogwang R, Murugu L, Nkumama IN, Nyamako L, Kai O, Mwai K, Murungi L, Idro R, Bejon P, Tuju J, Kinyanjui SM, Osier FHA
Front Immunol, (2024). 15:1360220
Editorial: Malaria molecular epidemiology current situation in Africa.Tandoh KZ, Duah-Quashie NO, Raman J, Ochola-Oyier LI
Front Epidemiol, (2024). 4:1400612
Designing and delivering bioinformatics project-based learning in East Africa.Kibet CK, Entfellner JD, Jjingo D, de Villiers EP, de Villiers S, Wambui K, Kinyanjui S, Masiga D
BMC Bioinformatics, (2024). 25:150
Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, Mwapasa V, Moore KA, Kwambai TK, Hamel MJ, Gyan T, Westercamp N, Kapito-Tembo A, Njuguna P, Ansong D, Kariuki S, Mvalo T, Snell P, Schellenberg D, Welega P, Otieno L, Chimala A, Afari EA, Bejon P, Maleta K, Agbenyega T, Snow RW, Zulu M, Chinkhumba J, Samuels AM
Lancet, (2024). 403:1660-1670
Childhood growth during recovery from acute illness in Africa and South Asia: a secondary analysis of the childhood acute illness and nutrition (CHAIN) prospective cohort.Bourdon C, Diallo AH, Mohammad Sayeem Bin Shahid AS, Khan MA, Saleem AF, Singa BO, Gnoumou BS, Tigoi C, Otieno CA, Oduol CO, Lancioni CL, Manyasi C, McGrath CJ, Maronga C, Lwanga C, Brals D, Ahmed D, Mondal D, Denno DM, Mangale DI, Chimwezi E, Mbale E, Mupere E, Salauddin Mamun GM, Ou�draogo I, Berkley JA, Njunge JM, Njirammadzi J, Mukisa J, Thitiri J, Walson JL, Jemutai J, Tickell KD, Shahrin L, Mallewa M, Hossain MI, Chisti MJ, Timbwa M, Mburu M, Ngari MM, Ngao N, Aber P, Harawa PP, Sukhtankar P, Bandsma RHJ, Bamouni RM, Molyneux S, Mwaringa S, Shaima SN, Ali SA, Afsana SM, Banu S, Ahmed T, Voskuijl WP, Kazi Z
EClinicalMedicine, (2024). 70:102530
Antibody-Dependent Respiratory Burst against Plasmodium falciparum Merozoites in Individuals Living in an Area with Declining Malaria Transmission.Mutemi DD, Tuju J, Ogwang R, Nyamako L, Wambui KM, Cruz IR, Villner P, Yman V, Kinyanjui SM, Rooth I, Ngasala B, F�rnert A, Osier FHA
Vaccines (Basel), (2024). 12:
Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.Kapulu MC, Muthumbi E, Otieno E, Rossi O, Ferruzzi P, Necchi F, Acquaviva A, Martin LB, Orindi B, Mwai K, Kibet H, Mwanzu A, Bigogo GM, Verani JR, Mbae C, Nyundo C, Agoti CN, Nakakana UN, Conti V, Bejon P, Kariuki S, Scott JAG, Micoli F, Podda A
Front Immunol, (2024). 15:1340425
Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.Kapulu M, Manda-Taylor L, Balasingam S, Means G, Ayiro Malungu M, Bejon P, Chi PC, Chiu C, Church EC, Correa-Oliveira R, Day N, Durbin A, Egesa M, Emerson C, Jambo K, Mathur R, Metzger W, Mumba N, Nazziwa W, Olotu A, Rodgers J, Sinyiza F, Talaat K, Kamerling I, Weller C, Baay M, Neels P
Biologicals, (2024). 85:101747
Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.Cavaleri M, Kaslow D, Boateng E, Chen WH, Chiu C, Choy RKM, Correa-Oliveira R, Durbin A, Egesa M, Gibani M, Kapulu M, Katindi M, Olotu A, Pongsuwan P, Simuyandi M, Speder B, Talaat KR, Weller C, Wills B, Baay M, Balasingam S, Olesen OF, Neels P
Biologicals, (2024). 85:101745
Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines.Juan-Giner A, Warimwe G
Lancet Infect Dis, (2024). S1473-3099:00008-2
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS, Dicko A, Tinto H, Ou�draogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS
Lancet, (2024). 403:533-544
Distinct transcriptomic signatures define febrile malaria depending on initial infective states, asymptomatic or uninfected.Kimenyi KM, Akinyi MY, Mwikali K, Gilmore T, Mwangi S, Omer E, Gichuki B, Wambua J, Njunge J, Obiero G, Bejon P, Langhorne J, Abdi A, Ochola-Oyier LI
BMC Infect Dis, (2024). 24:140
Sugar and blood: the nutritional priorities of the dengue vector, Aedes aegypti.Tenywa FC, Musa JJ, Musiba RM, Swai JK, Mpelepele AB, Okumu FO, Maia MF
Parasit Vectors, (2024). 17:26
Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration .Kagucia EW, Voller S, Ziraba AK, Bigogo G, Munywoki PK, Makobu K, Nokes DJ, Nyagwange J, Orlendo C, Akech D, Sigilai A, Onyango C, Juma B, Herman-Roloff A, Munyua P, Apondi C, Lidechi S, Audi A, Ouma A, Aol G, Misore T, Nasimiyu C, Onyango D, Lo T, Kasera K, Jalang'o R, Kingwara L, Adetifa I, Etyang AO, Warimwe G, Agweyu A, Scott JAG
Gates Open Res, (2024). 8:
Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study.Kimotho J, Sein Y, Sayed S, Shah R, Mwai K, Saleh M, Wanjiku P, Mwacharo J, Nyagwange J, Karanja H, Kutima B, Gitonga JN, Mugo D, Karanu A, Moranga L, Oluoch V, Shah J, Mutiso J, Mburu A, Nneka Z, Betti P, Mutinda WU, Issak Abdi A, Bejon P, Ochola-Oyier LI, Warimwe GM, Nduati EW, Ndungu FM
Wellcome Open Res, (2023). 8:350
Utility of MALDI-TOF MS for determination of species identity and blood meal sources of primary malaria vectors on the Kenyan coast.Karisa J, Ominde K, Tuwei M, Bartilol B, Ondieki Z, Musani H, Wanjiku C, Mwikali K, Babu L, Rono M, Eminov M, Mbogo C, Bejon P, Mwangangi J, Laroche M, Maia M
Wellcome Open Res, (2023). 8:151
Safety and immunogenicity of varied doses of R21/Matrix-M� vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang S, Datoo MS, Otieno E, Muiruri C, Bellamy D, Gathuri E, Ngoto O, Musembi J, Provstgaard-Morys S, Stockdale L, Aboagye J, Woods D, Lawrie A, Roberts R, Keter K, Kimani D, Ndungu F, Kapulu M, Njau I, Orindi B, Ewer KJ, Hill AVS, Bejon P, Hamaluba M
Wellcome Open Res, (2023). 8:450
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G
Wellcome Open Res, (2023). 8:182
Low frequency of Plasmodium falciparum hrp2/3 deletions from symptomatic infections at a primary healthcare facility in Kilifi, Kenya.Okanda D, Ndwiga L, Osoti V, Achieng N, Wambua J, Ngetsa C, Lubell-Doughtie P, Shankar A, Bejon P, Ochola-Oyier LI
Front Epidemiol, (2023). 3:1083114
